Altimmune, Inc. (ALT)

16.90 +2.55 (+17.77%) At close: 4:00PM EST

Altimmune, Inc.

910 Clopper Road
Suite 201S
Gaithersburg, MD 20878
United States
240-654-1450
http://altimmune.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 25

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Vipin K. Garg	Pres, CEO & Director	566.63k	N/A	1958
Mr. William Michael Brown	CFO & Principal Accounting Officer	443.16k	N/A	1982
Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF	Chief Medical Officer	371.29k	N/A	1953
Mr. Bertrand Georges Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Dr. M. Scot Roberts	Chief Scientific Officer	N/A	N/A	1959
Mr. José Ochoa	Chief Bus. Officer	N/A	N/A	N/A

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.

Corporate Governance

Altimmune, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.